Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sten Stovall

London, UK
Sten Stovall is a London-based editor and writer with 40 years of experience in the field of journalism, including more than 20 years with Reuters and eight years with The Wall Street Journal/Dow Jones Newswires. He also has wide radio and television reporting experience and a solid network of contacts in the biopharma world. Sten is part of our team of specialist reporters, generating insightful features and analysis about R&D, product development, regulatory issues and industry trends for publications such as "The Pink Sheet", Scrip and IN VIVO.
Advertisement
Set Alert for Articles By Sten Stovall

Latest From Sten Stovall

Roche Says MS Drug Ocrevus Launch Its 'Best So Far', Vows To Help US Reform

Roche said MS drug Ocrevus should generate sales of CHF2bn in its first full year after launch. The Swiss group also pledged to actively help the Trump Administration with its healthcare reform program.

Sales & Earnings Companies

Merck KGaA Foresees Mid-2019 US Launch Of Oral MS Therapy Mavenclad

German Merck tells Scrip Mavenclad's long spell in the regulatory 'wilderness' allowed it to amass deep safety and efficacy data that should help the oral MS drug's commercial prospects.

Business Strategies Launches

Merck of Germany's Hunt For MS BTKi Partner Boosted By Evobrutinib Data

German Merck tells Scrip its quest to find a partner for its Bruton’s tyrosine kinase inhibitor evobrutinib should be helped by positive 24-week Phase IIb data in relapsing multiple sclerosis.

Clinical Trials Companies

Analysts Up-Beat On Xencor's XmAB5871 Despite Phase II 'Placebo Hiccup' in SLE

Analysts shrugged off mixed topline data from a Phase II study showing Xencor’s lead compound XmAb5871 missed its primary endpoint in systemic lupus erythematosus (SLE), blaming the miss on the number of patients dropping out of the placebo arm of the trial.  

Clinical Trials Immune Disorders

VelosBio CEO: Series A Success Shows Investors Back His ADC Formula

VelosBio's well-backed Series A funding round showed that investors believe his team has identified the right combination of cancer target, linker and payload for creating a successful novel ADC, the biotech's CEO told Scrip.

Research and Development Strategies Financing

For Artificial Intelligence To Save Lives And Money, 'It Must Be Trusted'

AI is already transforming healthcare. But a successful evolution of machine learning in the sector demands ethical and practicable regulations that ensure public trust and a road map for innovative companies and end-users, a London conference heard. Scrip was there.

Artificial Intelligence Commercial
See All
Advertisement
UsernamePublicRestriction

Register